Venlafaxine (SNRI)
Treatment for Depression
Typical Dosage: 75-225mg daily (extended-release)
Effectiveness
80%
Safety Score
60%
Clinical Trials
18
Participants
80K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
75-225mg daily (extended-release)
Time to Effect
2-4 weeks
Treatment Duration
Acute: 6-12 weeks; Continuation: 4-9 months; Maintenance: 1-2+ years
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
18(Treat 18 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$300
Monitoring:$1,000
Side Effect Mgmt:$200
Total Annual:$1,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$40,000/QALY
QALYs Gained
0.35
Outcome-Based Costs
Cost per Responder
$2,419
Cost per Remission
$3,750
Venlafaxine (SNRI) Outcomes
for Depression
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+62%
Remission Rate
+40%
Common Side Effects
Nausea
+35%
Insomnia
+25%
Sweating
+20%
Sexual dysfunction
+50%
Blood pressure increase
+10%
Sources:
Active Clinical Trials
5 active trials recruiting for Venlafaxine (SNRI) in Depression
Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia
NCT07120880NOT YET RECRUITINGPHASE3
184 participants
INTERVENTIONAL
Paris, France
Started: Sep 1, 2025
Implementation of Personalized Medicine for Optimal Drug Therapy in Cancer
NCT05830279RECRUITING
600 participants
OBSERVATIONAL
London, Canada
Started: May 1, 2023
Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression
NCT06591091NOT YET RECRUITINGPHASE2
80 participants
INTERVENTIONAL
Started: Sep 1, 2025
Neurobiological and Genomic Predictors of Relapse in Depression
NCT07328373RECRUITING
204 participants
OBSERVATIONAL
Istanbul, Turkey (Türkiye)
Started: Jan 1, 2025
A Study on Functional Connectome and rTMS Intervention of Cognitive Flexibility Impairment in Patients With Major Depressive Disorder
NCT07161492NOT YET RECRUITINGNA
182 participants
INTERVENTIONAL
Changsha, China
Started: Sep 1, 2025
Completed Clinical Trials
10 completed trials for Venlafaxine (SNRI) in Depression
Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury
NCT02320240COMPLETED
3.26M participants
OBSERVATIONAL
Montreal, Canada
Started: Jun 1, 2013
Assessment of Pituitary Adenylate Cyclase Activating Polypeptide-Brain Derived Neurotrophic Factor (PACAP-BDNF) Signaling System Involvement in Etiology and Treatment of Major Depression
NCT00944996COMPLETEDNA
100 participants
INTERVENTIONAL
Tirat Hacarmel, Israel
Started: Jun 1, 2009
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
NCT03321526COMPLETEDPHASE2
107 participants
INTERVENTIONAL
Phoenix, United States +49 more
Started: Dec 12, 2017
Multiple Ascending Dose Phase 1 Study of ALA-3000
NCT06965569COMPLETEDPHASE1
37 participants
INTERVENTIONAL
Little Rock, United States +3 more
Started: Apr 21, 2025
Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder
NCT05952713COMPLETED
73.3K participants
OBSERVATIONAL
Copenhagen, Denmark
Started: Oct 1, 2022
Anxiety and Depression in Epilepsy: A Treatment Study
NCT03464383COMPLETEDPHASE4
69 participants
INTERVENTIONAL
Winston-Salem, United States
Started: May 7, 2018
Patient Dimensions as Predictors of Varied Treatment Responses and Outcomes in Patients With Major Depression
NCT00744406COMPLETEDPHASE2
72 participants
INTERVENTIONAL
Toronto, Canada
Started: Jul 1, 2003
Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury
NCT00735670COMPLETEDNA
34 participants
INTERVENTIONAL
Ann Arbor, United States
Started: Jun 1, 2008
Stress Generation and Recurrent Depression: The Role of Differential Treatment Response
NCT00745017COMPLETEDPHASE1
72 participants
INTERVENTIONAL
Toronto, Canada
Started: Jul 1, 2001
eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk
NCT04437485COMPLETEDPHASE2
46 participants
INTERVENTIONAL
Indianapolis, United States
Started: Oct 14, 2020